Investigator studied current treatment patterns and attrition rates in metastatic clear cell renal cell carcinoma using a large, US nationwide cohort.

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

The arrival of oral tyrosine kinase inhibitors (TKIs) radically changed the treatment paradigm in EGFR-mutated advanced non-small cell lung cancer (NSCLC), and this was followed by development of ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

Using data from approximately 280 cancer clinics in the US nationwide ... In cohort 1, the most common first-line treatments were tyrosine kinase inhibitors (TKI; 78.8%), followed by mammalian ...